Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 4 min ago

IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor

Wed, 03/19/2014 - 15:40
Cesium-131 Implants Used to Provide Needed Radiation to Treat This Aggressive Cancer RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR) (http://www.isoray.com/), a medical technology company and innovator in seed brachyth...
Devices, Oncology
IsoRay, brachytherapy, Cesium-131, radiotherapy

Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.

Wed, 03/19/2014 - 15:33
87.9% of Cadence’s outstanding shares were validly tendered, and subsequent merger has been completed Addition of high-growth OFIRMEV®, a differentiated pain product, will expand Mallinckrodt’s U.S. hospitals channel DUBLIN--(Healthcare Sales &...
Biopharmaceuticals, Mergers & Acquisitions
Mallinckrodt, Cadence Pharmaceuticals, OFIRMEV, acetaminophen

Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer

Wed, 03/19/2014 - 15:30
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--Mirna Therapeutics (Mirna), a private, clinical stage biopharmaceutical company focused on the development of microRNA-based oncology therapeutics, today announced Casi DeYoung has joined the company a...
Biopharmaceuticals, Oncology, Personnel
Mirna Therapeutics, microRNA

Novira Names Christian S. Schade Chief Executive Officer

Wed, 03/19/2014 - 15:26
DOYLESTOWN, Pa., March 19, 2014 -- (Healthcare Sales & Marketing Network) -- Novira Therapeutics, Inc., today announced that Christian S. Schade has been named Chief Executive Officer, effective March 19. Mr. Schade has more than 30 years of extensive ...
Biopharmaceuticals, Personnel
Novira Therapeutics, HBV

Volcano Announces FDA Clearance of its Proprietary iFR(R) (instant wave-Free Ratio(TM)) Modality and Immediate Commencement of U.S. Limited Market Release

Wed, 03/19/2014 - 14:50
SAN DIEGO, March 19, 2014 -- (Healthcare Sales & Marketing Network) -- Volcano Corporation (VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular di...
Devices, Interventional Cardiology, FDA, Product Launch
Volcano, wave-Free Ratio, iFR Modality, Fractional Flow Reserve

Healthcare Startup Augmedix Announces $3.2 Million in Venture Funding

Wed, 03/19/2014 - 14:23
First and largest Google Glass startup poised to revolutionize healthcare SAN FRANCISCO, March 19, 2014 -- (Healthcare Sales & Marketing Network) -- Today, Augmedix announced that it has received venture funding from DCM and Emergence Capital Partners....
Devices, Venture Capital
Augmedix, Google Glass

Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma plc

Wed, 03/19/2014 - 14:11
Accelerates Horizon's Transformation to a Profitable Specialty Pharma Company Expected Pro Forma Combined, Full Year 2014 Revenues of $250 to $265 Million and EBITDA(1) of $65 to $75 Million Vidara Recorded $58.9 Million of ACTIMMUNE® Net Sales i...
Biopharmaceuticals, Mergers & Acquisitions
Horizon Pharma, Vidara Therapeutics

RaySearch Secures Distribution of Raystation(R) in Australia and New Zealand

Wed, 03/19/2014 - 14:06
STOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (STO:RAYB) has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means th...
Devices, Oncology, Distribution
RaySearch Laboratories, AlphaXRT, RayStation

BioAlliance Pharma: Sitavig(R) Licensing Strategy

Wed, 03/19/2014 - 13:15
Execution of licensing agreement with Innocutis for North America Positive opinion from French and German Health Authorities for Marketing Authorization PARIS--(Healthcare Sales & Marketing Network)--BioAlliance Pharma SA (BIO.PA), an innovative Com...
Biopharmaceuticals, Dermatology, Licensing
BioAlliance Pharma, Sitavig, acyclovir Lauriad, Innocutis

On-X Life Technologies Prepares European Sales Force to Sell On-X(R) Plus 1.5(TM) Aortic Heart Valve

Tue, 03/18/2014 - 15:16
“While the On-X® Plus 1.5™ Aortic Heart Valve represents a new paradigm by which clinicians can manage their patients on a reduced dose of warfarin, we are proud to note that On-X has been successfully selling mechanical valves in Europe since July 199...
Devices, Cardiology, Product Launch
On-X Life Technologies, aortic valve, heart valve

St. Jude Medical Announces Start of European Post-Approval Trial for Nanostim Leadless Pacemaker

Tue, 03/18/2014 - 15:11
Large European clinical trial to continue building evidence supporting strong safety profile and performance of the world’s first leadless pacemaker ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical...
Devices, Cardiology
St. Jude Medical, Nanostim, leadless, pacemaker

CeloNova’s Coronary Stent System Could Mean Faster Healing of Arteries and Greatly Reduced Use of Blood-thinning Medication

Tue, 03/18/2014 - 15:06
SAN ANTONIO--(Healthcare Sales & Marketing Network)--CeloNova BioSciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigative device exemption (IDE) trial for its novel coronary stent syste...
Devices, Interventional Cardiology, FDA
CeloNova BioSciences, Cobra PzF, coronary stent

Immune Design Appoints Franklin M. Berger to Board of Directors

Tue, 03/18/2014 - 14:53
SEATTLE and SOUTH SAN FRANCISCO, Cali., March 18, 2014 -- (Healthcare Sales & Marketing Network) -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, t...
Biopharmaceuticals, Oncology, Personnel
Immune Design, cytotoxic T cells, immunotherapy

Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors

Tue, 03/18/2014 - 14:50
SOUTH SAN FRANCISCO, Calif., March 18, 2014 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals (PTLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as c...
Biopharmaceuticals, Personnel
Portola Pharmaceuticals, Betrixaban, Andexanet Alfa, Cerdulatinib

NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

Tue, 03/18/2014 - 14:46
Company is First to Offer Plasma-Based Next Generation Sequencing Tests FORT MYERS, Fla., March 18, 2014 -- (Healthcare Sales & Marketing Network) -- NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic and molecular testing services, ...
Diagnostics, Oncology, Product Launch
NeoGenomics, myelodysplastic syndrome

FDA Advisory Panel Votes in Favor of STAAR Surgical's Visian(R) Toric Implantable Collamer(R) Lens, TICL(TM)

Tue, 03/18/2014 - 00:31
First of Kind Product in the U.S. MONROVIA, Calif., March 17, 2014 -- (Healthcare Sales & Marketing Network) -- STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye and delivery systems reporte...
Devices, Ophthalmology, FDA
STAAR Surgical, Visian, Toric Implantable Lens

Mevion Medical Systems Delivers its MEVION S250 Proton Accelerator to First Coast Oncology in Jacksonville, Florida

Mon, 03/17/2014 - 18:55
LITTLETON, Mass.--(Healthcare Sales & Marketing Network)--Mevion Medical Systems announced today the delivery of its revolutionary MEVION S250 proton therapy superconducting synchrocyclotron accelerator to the world’s first physician-owned proton therapy c...
Devices, Oncology
Mevion Medical Systems, Proton Beam, proton therapy, radiotherapy

Hokkaido University and Hitachi Complete a Facility Incorporating a Novel Proton Beam Therapy System for Cancer Treatment Developed Jointly under Japan's FIRST Program

Mon, 03/17/2014 - 18:53
SAPPORO, Japan--(Healthcare Sales & Marketing Network)--Hokkaido University and Hitachi, Ltd. (TSE:6501) today announced that they have completed construction of facilities incorporating the “PROBEAT-RT Proton Beam Therapy System,” a novel proton beam canc...
Devices, Oncology
Hitachi, PROBEAT-RT, Proton Beam, proton therapy, radiotherapy

BioCardia(R) Receives CE Mark for Morph AccessPro(TM) Steerable Introducer

Mon, 03/17/2014 - 18:49
SAN CARLOS, Calif.--(Healthcare Sales & Marketing Network)--BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced receipt of the CE Mark for its Morph AccessPro™ Steerable Introducer, designed for easier navigation through...
Devices, Interventional Cardiology, Regulatory
BioCardia, Morph AccessPro, Steerable Introducer

Clarus Therapeutics Appoints John Gargiulo Chief Operating Officer

Mon, 03/17/2014 - 16:22
Seasoned Pharmaceutical Executive to Lead Planned Commercialization of REXTORO(TM) NORTHBROOK, Ill., March 17, 2014 -- (Healthcare Sales & Marketing Network) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the de...
Biopharmaceuticals, Personnel
Clarus Therapeutics, REXTORO, testosterone

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong